LEVODOPA COMBINED WITH MK 486 (L‐ALPHA METHYLDOPAHYDRAZINE)—A PERIPHERAL DECARBOXYLASE INHIBITOR IN PARKINSON'S DISEASE

Abstract
A single blind trial using placebo MK 486 in seven patients over 12 weeks and active MK 486 (L‐alpha methyldopahydrazine) over 20 weeks in 12 Parkinsonian patients on L‐dopa therapy reveals that pati...